Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts Daniel L. GustafsonBarbara FrederickDavid Raben Original Article 29 March 2007 Pages: 179 - 188
Cell death in response to antimetabolites directed at thymidylate synthase Karen W. BarbourFranklin G. Berger Original Article 30 March 2007 Pages: 189 - 201
A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro Peter AndrewsXu ZhaoMelissa Chang Original Article 20 April 2007 Pages: 203 - 214
Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster R. F. C. LeitãoR. A. RibeiroG. A. C. Brito Original Article 11 April 2007 Pages: 215 - 222
Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis Sandhya Kiran ApparajuGary A. GudelskyPankaj B. Desai Original Article 19 April 2007 Pages: 223 - 229
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells David H. HolmanLorianne S. TurnerJames S. Norris Original Article 12 April 2007 Pages: 231 - 242
Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO Jalid SehouliDirk Stengelon behalf of the Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) Original Article 29 March 2007 Pages: 243 - 250
The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner Hellinida ThomadakiAndreas ScorilasMaria Havredaki Original Article 09 May 2007 Pages: 251 - 265
Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p′-DDD (mitotane) in Minipigs Veronica HermanssonTatiana CantillanaIngvar Brandt Original Article 12 April 2007 Pages: 267 - 274
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer Takeshi KatoHideyuki MishimaMorito Monden Original Article 11 April 2007 Pages: 275 - 281
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer Bassel F. El-RayesMark M. ZalupskiPhilip A. Philip Original Article 12 April 2007 Pages: 283 - 289
Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system Mark N. KirsteinRichard C. BrundageDouglas Yee Original Article 12 April 2007 Pages: 291 - 299
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy Jong Gwang KimBaek-Yeol RyooYoon-Koo Kang Original Article 12 April 2007 Pages: 301 - 307
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy Hye Jin ChoiByoung Chul ChoJoo Hang Kim Original Article 19 June 2007 Pages: 309 - 313
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer Chong Kun ImHei-Cheul JeungHyun Cheol Chung Original Article 02 June 2007 Pages: 315 - 321
Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization Timothy J. KinsellaMichael T. KinsellaPatricia J. Tosca Original Article 12 June 2007 Pages: 323 - 334
Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients Takeharu YamanakaShigemi MatsumotoMasanori Fukushima Original Article 09 October 2007 Pages: 335 - 343
Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine Brian S. ChoiH. Ian Robins Short Communication 20 March 2007 Pages: 345 - 346
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy Gregor FürstenbergerPeter SchmidHans-Jörg Senn Short Communication 25 September 2007 Pages: 347 - 348